Our lawyers are reviewing Elmiron lawsuits for victims who have suffered maculopathy or other eye conditions as a result of the use of Elmiron. There are now only 273 class action lawsuits filed as of June 15, 2021. But our Elmiron lawyers believe that number could soon be over 1,000 lawsuits.
[July 2021 Update: In December 2020, the Judicial Panel on Multidistrict Litigation created a new MDL class action for the consolidated handling of all Elmiron lawsuits in federal courts. The Elmiron MDL (In Re: Elmiron (Pentosan Polysulfate Sodium) Prod. Liab. Litigation, MDL 2973) was established in the U.S. District Court for New Jersey under Judge Brian Martinotti. Judge Martinotti is a seasoned class action judge.
As of July 2021, the Elmiron MDL class action had 273 individual pending cases. Another 43 Elmiron lawsuits pending in state courts in New Jersey and Pennsylvania. Liaison counsel and steering committees have been selected for both the plaintiff and defense sides.
In May 2021, Judge Martinotti ordered the parties to prepare a bellwether test trial plan with the first Elmiron bellwether trial to be held in January 2023.
Yes, 18 months is a long way away. But getting a trial date is a big deal. Our Elmiron lawsuit attorneys' prediction - and it is just a prediction - is an Elmiron global settlement will occur before a single Elmiron lawsuit goes to trial. We believe these are very strong cases for the plaintiffs.]]
New studies suggest that Elmiron causes retinal damage to the eyes. One study confirmed that Elmiron can cause a serious eye disease called maculopathy which can result in blindness in potentially one-fourth of the patients who took this drug.
This is a pretty staggering number, right? Our class action lawyers rarely see mass torts with a risk of injury as high as it is with Elmiron. Let's say this number is off by half. That would still be a tragic number of victims.
Anyone who used the drug Elmiron and has been diagnosed with maculopathy or other eye conditions may be entitled to financial compensation from the drug manufacturer. Our law firm is currently accepting new cases from anyone who used this prescription medication and has been diagnosed with pigmentary maculopathy, macular degeneration, or other conditions.
These lawsuits are growing quickly. The quirky thing about this litigation is that Elmiron users will often not link their vision issues to the drug. The cause of these vision loss injuries will often be misdiagnosed -- they have already been told by a doctor there was some other cause for the eye injury. But when awareness of the side effects of Elmiron increases, the number of victims lawyers will see will increase accordingly.
Elmiron is the popular brand name of a drug called pentosan polysulfate sodium. Pentosan polysulfate belongs to a family of anticoagulant drugs known as low molecular weight herapins. Most drugs in this category are used as blood thinners, but Elmiron is used for the treatment of a condition called interstitial cystitis.
Interstitial cystitis (“IC”) is a bladder condition that causes chronic and pain and discomfort as well as urinary frequency. As many as 12 million people in the U.S. currently suffer from IC. Elmiron helps to treat the symptoms of IC by preventing irritation and swelling of the walls of the bladder. The drug is thought to function as a synthetic mucus layer around the bladder to guard against irritation.
Elmiron was developed and manufactured by Janssen Pharmaceuticals Inc., which is a corporate subsidiary of Johnson & Johnson. Elmiron was first approved by the FDA back in 1996 and since then it has become the standard treatment option for individuals suffering from IC. Elmiron is also sometimes used to treat bladder pain associated with urinary tract infections.
Elmiron is still the only drug currently approved by the FDA for the treatment of IC-related bladder pain. Millions of people take it every day and Janssen has and continued to make a fortune from this drug.
But the question that will be the focus of this litigation is when did Janssen first learn of the risks of this drug. Janssen may be arguing at trial that it was the last to know. This will be a hard argument to sell, right?
Over 90 Elmiron lawsuits have been filed as of March 2021. More victims are hiring a lawyer. A class action MDL has just been created. There are many more Elmiron eye injury lawsuits coming in the months ahead. You should act now if you have an Elmiron claim.
There is also, parenthetically, some argument from some Elmiron lawyers that this drug is not an efficacious treatment for IC. They point to studies suggesting that Elmiron performs no better than placebo for some IC complications.
If this argument carries water, it underscores that the risk hardly worth the benefits. But, either way, the case comes down to whether Elmiron's side effects require warning based on the information that was available that communicated the risk of a vision-related injury.Evidence Links Elmiron to Serious Eye Damage
There is strong evidence that Elmiron causes an eye disorder called retinal maculopathy. Long-term exposure appears to increase the risks.
Since its initial release back in 1996, Elmiron has always been viewed as a relatively safe drug with few significant risks or serious side effects. All that has changed very drastically in the last year.
The discovery of Elmiron’s toxicity began in 2018 when doctors from the Emory Eye Center in Atlanta, Georgia started noticing a strange trend. They had 6 patients with abnormal damage to the macula region of their eyes and were diagnosed with pigmentary maculopathy.
The doctors eventually realized that all of these patients were long-term users of the drug Elmiron. This led the Emory Eye Center to publish a preliminary report which suggested that Elmiron may be toxic to retinal tissue in the human eye.
This warning call immediately prompted a more detailed study into the safety of Elmiron and its potential toxicity to the eyes. This was done by a team of ophthalmologists in Northern California based on thousands of patient records. The alarming results of this research were presented at the annual meeting of the American Academy of Ophthalmology in October 2019.
The study results showed very conclusively that Elmiron was very toxic to the sensitive retina tissue in the back of the eyes. About 25% of patients who used Elmiron displayed signs of maculopathy or significant eye damage. Many of these victims already have partial or total loss of their vision. When these individuals were examined and tested, doctors found clear signs of drug toxicity related to their prolonged use of Elmiron.
July 2021 Update: Sometimes in lawsuits like these Elmiron claim, the scientific literature looks promising but turns in favor of the defendants. The medical literature in this case that is now coming out continues to support the arguments plaintiffs' Elmiron class action lawyers are making. A Northwestern University study looked at the presence of Elmiron-related maculopathy. Researchers examined the medical records of 131 Elmiron patients. Forty underwent imaging and 91 underwent fundus examinations.
The researchers' data revealed 10 patients with Elmiron-related maculopathy signs. Half of them underwent imaging, while the other half underwent fundus examinations. They also found that these 10 patients took Elmiron for an average of 4.2 years with an average cumulative dose of 380g.
The researchers inferred that imaging could detect Elmiron-related maculopathy. Which tells you... Elmiron can cause maculopathy.
Recent studies have linked prolonged use of Elmiron to maculopathy, which is also known as macular retinopathy. Maculopathy is a broad term for any disease or pathologic condition affecting the macula – the central region of the retina in the eye. The type of maculopathy directly associated with Elmiron is called pigmentary maculopathy.
However, macular damage from Elmiron can easily be misdiagnosed as age-related macular degeneration. Maculopathy can result in impairment or even loss of vision.Elmiron Lawsuits for Vision Loss Maculopathy
Hundreds of thousands of people have been exposed to Elmiron: the drug is still on the market.
The recent evidence showing that Elmiron causes serious eye damage is going to lead to a wave of lawsuits against the drug’s manufacturer. If you took Elmiron and were subsequently diagnosed with eye problems involving the retina such as maculopathy the drug maker can be held liable for your injuries.
There is already sufficient evidence establishing a link between Elmiron and retinal damage to support a product liability lawsuit. Hundreds and possibly thousands of Elmiron vision loss lawsuits are expected to be filed against Janssen Pharmaceutical.Our Lawyers Are Accepting New Elmiron Eye Damage Lawsuits
Our Elmiron lawyers are taking new Elmiron class action lawsuit cases for victims seeking compensation. We are looking for individuals suffering from side effects who meet the following basic criteria:
- You took Elmiron on a daily for 6-months or longer; and
- After using Elmiron you experienced vision problems and were diagnosed with any of the following conditions:
- Maculopathy/macular retinopathy
- Age-related macular degeneration
- Retinal dystrophy
- Other retinal conditions
If you or a family member meet these criteria, contact our law office today for a free consultation to find out if you qualify for an Elmiron eye injury lawsuit.
Plaintiffs' lawyers are at an early stage of the Elmiron eye damage litigation. Eighty Elmiron lawsuits have been filed against Janssen Pharmaceutical. Why are things moving slowly? People are just starting to connect Elmiron to their vision-related injuries. Everyone is fully expecting several thousands of individual Elmiron eye damage lawsuits to get filed eventually.
At some point in the next few months, all Elmiron cases in the federal court system will likely be consolidated into an MDL class action.
An MDL is similar to a class action lawsuit. All pending cases from around the country involving a single defective drug or product are consolidated for litigation under a single federal judge for pretrial discovery.
Claim details and basic information is gathered and compiled for all of the plaintiffs. Then a few individual “test” cases will be selected for trial and the results of those trials are used to negotiate a global settlement of all the remaining cases. Usually, the settlement has tiers or levels of payments to plaintiffs based on the severity of their injuries.
In addition to Janssen, other defendants in this litigation include Teva, Bayer, Alza, Centocor, Ortho-McNeil, and IVAX.Potential Elmiron Lawsuit Settlement Compensation
Right now the first Elmiron eye damage lawsuits are just getting filed, so we have no way of knowing for sure what the Elmiron settlement amounts will be. But we can estimate the value of the Elmiron cases by comparing them to the settlement amounts of prior cases involving similar injuries.
Please keep in mind we are making a lot of assumptions here based on very little information. It is too early to accurately predict the expected settlement amounts of these vision loss lawsuits. But people want to know what the settlement compensation payout could be so we give our unvarnished opinion.
The victims in the Elmiron lawsuits will have the same basic injuries - vision impairment, macular degeneration, and loss of vision. The settlement value of vision loss or vision impairment injuries in other cases is a lens to the settlement values in the Elmiron litigation. Based on this data, our Elmiron lawyers anticipate that cases in which the plaintiff suffered total vision loss may have a settlement value of $1,000,000 or more.
Is this speculation? Of course it is. We keep beating this drum - anything can happen in the litigation, it is still very early. But you do not need to be a class action lawyer for 25 years to understand that losing your vision is an awful injury that deserves a great deal of compensation if the defendants are culpable.
Elmiron cases involving only vision impairment will likely be grouped into tiers based on the level of impairment to the plaintiff’s vision. The most serious injuries will involve permanent vision loss. Plaintiffs with the most extensive impairment to their vision (maybe 75%-80% impairment) will be in the top settlement tier (“tier 1). Plaintiffs with less impairment (40%-75%) will be in the next tier (“tier 2”) and there will likely be 2 or more lower tiers after that.
Based on average case values in other vision impairment lawsuits, we guess/believe that Elmiron vision loss impairment cases in tier 1 may have settlement value in the range of $300,000 to $600,000. Cases in tier 2 may have a settlement range somewhere between $75,000 and $250,000. Are these numbers realistic? Our law firm is particularly bullish on the value of these cases.Example Elmiron Lawsuits
Below are two recently filed Elmiron lawsuits.
- Montgomery v. Janssen Pharmaceuticals, et al: This lawsuit filed in August 2020 in Florida alleges that as a result of her use of Elmiron, the plaintiff suffers from severe maculopathy in both eyes that have caused blurry vision, night blindness, difficulty adjusting to dim lighting, dark/blank spots in her field of vision, straight lines appearing curved or squiggly, difficulty reading, and difficulty seeing colors.
- Johns v. Janssen Pharmaceuticals, et al: This suit filed in August 2020 in New Jersey alleges that Janssen knew of the grave risks of the long-term use of Elmiron included retinal damage that could cause severe vision impairment yet failed to communicate these concerns to doctors and patients.
- Worden v Janssen Pharmaceuticals, et al. (New Jersey): The plaintiff is a middle-aged woman living in upstate New York who took Elmiron for IC on a daily basis for 17 years. In 2020, the plaintiff was diagnosed with maculopathy and retinal damage that has permanently impaired her vision. The complaint brings claims for Strict Liability; Breach of Warranty; Breach of Implied Warranty; Negligence; Negligence Per Se; and Negligent Misrepresentation. Named defendants included Janssen Pharmaceuticals Inc. (and 2 Janssen subsidiaries); Johnson & Johnson; and Ortho-McNeil Pharmaceuticals, Inc. The Complaint was filed in May 2020 in the U.S. District Court for New Jersey.
- Allen v Janssen Pharmaceuticals, et al. (Pennsylvania): This putative class action was filed by a middle-aged female from Illinois who took Elmiron regularly from 2009 to 2020 for the treatment of her interstitial cystitis condition. The plaintiff here has actually not been diagnosed with maculopathy or suffered any vision damage or impairment. Rather, the plaintiff is alleging that her use of Elmiron has placed her (and others in the proposed class) at an increased risk of severe visual injuries associated with Elmiron. This complaint seeks to force the defendants to establish a fund to pay for the plaintiff and other Elmiron users to have regular eye exams and diagnostic testing. This is called a medical monitoring lawsuit. The complaint was filed in the U.S. District Court in Philadelphia.
- 2021: Kalbag NS, et. al: Maculopathy Secondary to Pentosan Polysulfate Use: A Single-Center Experience. Clin Ophthalmol. 2021;15:513-519
- 2020: Doiron, RC, et. al: Possible drug-induced, vision-threatening maculopathy secondary to chronic pentosan polysulfate sodium (Elmiron®) exposure, Can Urol Assoc J. 2020 Feb; 14(2): 10–11, doi: 10.5489/cuaj.6401. This 2020 article, which came out after the Elmiron litigation, summarizes the literature and underscores the risks of newly understood risks of the drug.
- 2019: Jain N, et. al: Association of macular disease with long-term use of pentosan polysulfate sodium: Findings from a U.S. cohort. Br J Ophthalmol. 2019 Nov 6; doi: 10.1136/bjophthalmol-2019-314765
- 2018: Pearce, WA, et. al: Pigmentary Maculopathy Associated with Chronic Exposure to Pentosan Polysulfate Sodium, 2018 Nov;125(11):1793-1802. doi: 10.1016. This study found unique pigmentary maculopathy in six patients taking pentosan polysulfate sodium. This is the article that set off alarms in the medical and scientific community we talked about above.
Below are answers to commonly asked questions about the Elmiron eye damage lawsuits.
Use of Elmiron can cause blindness in certain patients. It was recently discovered that extended use of Elmiron can cause a very unique type of eye condition called pigmentary maculotpathy that can cause vision impairment and complete blindness.
We spell out the Elmiron lawsuit criteria above. Anyone who has been diagnosed with pigmentary maculopathy after taking the prescription injection drug Elmiron is eligible to bring an Elmiron injury lawsuit. Even if you have not been diagnosed with this specific condition you may still qualify if you took Elmiron and subsequently suffered vision impairment or blindness.
Right now individual Elmiron lawsuits are still being filed by plaintiffs around the country. All pending Elmiron suits in federal courts have been consolidated into an MDL in New Jersey and will undergo a collective process of civil discovery. (So if you file a case in federal court in, for example, California, it will be transferred to New Jersey.) Once this discovery phase ends test trials will be held and used to facilitate global settlement discussions.
Elmiron lawsuits could have a very high settlement value because of the serious nature of the injuries. Claims from Elmiron plaintiffs with total vision loss could be worth close to $1,000,000.
If you believe your vision was lost or impaired because you used this drug, call our Elmiron attorneys today at 800-553-8082 to discuss your legal options. You can also get a free case evaluation online.